Literature DB >> 27420606

Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study.

Andrew Schrepf1, Daniel E Harper1, Steven E Harte1, Heng Wang1, Eric Ichesco1, Johnson P Hampson1, Jon-Kar Zubieta2, Daniel J Clauw1, Richard E Harris1.   

Abstract

Endogenous opioid system dysfunction potentially contributes to chronic pain in fibromyalgia (FM), but it is unknown if this dysfunction is related to established neurobiological markers of hyperalgesia. We previously reported that µ-opioid receptor (MOR) availability was reduced in patients with FM as compared with healthy controls in several pain-processing brain regions. In the present study, we compared pain-evoked functional magnetic resonance imaging with endogenous MOR binding and clinical pain ratings in female opioid-naive patients with FM (n = 18) using whole-brain analyses and regions of interest from our previous research. Within antinociceptive brain regions, including the dorsolateral prefrontal cortex (r = 0.81, P < 0.001) and multiple regions of the anterior cingulate cortex (all r > 0.67; all P < 0.02), reduced MOR availability was associated with decreased pain-evoked neural activity. Additionally, reduced MOR availability was associated with lower brain activation in the nucleus accumbens (r = 0.47, P = 0.050). In many of these regions, pain-evoked activity and MOR binding potential were also associated with lower clinical affective pain ratings. These findings are the first to link endogenous opioid system tone to regional pain-evoked brain activity in a clinical pain population. Our data suggest that dysregulation of the endogenous opioid system in FM could lead to less excitation in antinociceptive brain regions by incoming noxious stimulation, resulting in the hyperalgesia and allodynia commonly observed in this population. We propose a conceptual model of affective pain dysregulation in FM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27420606      PMCID: PMC5028286          DOI: 10.1097/j.pain.0000000000000633

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  67 in total

1.  Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network.

Authors:  U Bingel; J Lorenz; E Schoell; C Weiller; C Büchel
Journal:  Pain       Date:  2005-12-20       Impact factor: 6.961

Review 2.  Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy.

Authors:  Richard E Harris; Daniel J Clauw
Journal:  Neurosci Lett       Date:  2012-03-22       Impact factor: 3.046

3.  Endogenous opioids released during non-nociceptive environmental stress induce latent pain sensitization Via a NMDA-dependent process.

Authors:  Chloé Le Roy; Emilie Laboureyras; Stéphanie Gavello-Baudy; Jérémy Chateauraynaud; Jean-Paul Laulin; Guy Simonnet
Journal:  J Pain       Date:  2011-07-01       Impact factor: 5.820

4.  Role of pain in placebo analgesia.

Authors:  J D Levine; N C Gordon; J C Bornstein; H L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

Review 5.  Fibromyalgia: from pathophysiology to therapy.

Authors:  Tobias Schmidt-Wilcke; Daniel J Clauw
Journal:  Nat Rev Rheumatol       Date:  2011-07-19       Impact factor: 20.543

6.  Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain.

Authors:  Larry F Chu; Nicole D'Arcy; Caitlin Brady; Abigail Kathleen Zamora; Chelsea Anne Young; Julie Eunwoo Kim; Anna Marie Clemenson; Martin S Angst; David J Clark
Journal:  Pain       Date:  2012-06-16       Impact factor: 6.961

7.  Increased density of mu-opioid receptors in the postmortem brain of suicide victims.

Authors:  A M Gabilondo; J J Meana; J A García-Sevilla
Journal:  Brain Res       Date:  1995-06-05       Impact factor: 3.252

8.  Altered quantitative sensory testing outcome in subjects with opioid therapy.

Authors:  Lucy Chen; Charlene Malarick; Lindsey Seefeld; Shuxing Wang; Mary Houghton; Jianren Mao
Journal:  Pain       Date:  2009-02-23       Impact factor: 6.961

9.  Keeping pain out of mind: the role of the dorsolateral prefrontal cortex in pain modulation.

Authors:  J Lorenz; S Minoshima; K L Casey
Journal:  Brain       Date:  2003-05       Impact factor: 13.501

10.  Pain catastrophizing and neural responses to pain among persons with fibromyalgia.

Authors:  R H Gracely; M E Geisser; T Giesecke; M A B Grant; F Petzke; D A Williams; D J Clauw
Journal:  Brain       Date:  2004-02-11       Impact factor: 13.501

View more
  41 in total

1.  Resting Functional Connectivity of the Periaqueductal Gray Is Associated With Normal Inhibition and Pathological Facilitation in Conditioned Pain Modulation.

Authors:  Daniel E Harper; Eric Ichesco; Andrew Schrepf; Johnson P Hampson; Daniel J Clauw; Tobias Schmidt-Wilcke; Richard E Harris; Steven E Harte
Journal:  J Pain       Date:  2018-01-31       Impact factor: 5.820

Review 2.  Neuroimaging of Pain: Human Evidence and Clinical Relevance of Central Nervous System Processes and Modulation.

Authors:  Katherine T Martucci; Sean C Mackey
Journal:  Anesthesiology       Date:  2018-06       Impact factor: 7.892

3.  Top down or bottom up? An observational investigation of improvement in fibromyalgia symptoms following hip and knee replacement.

Authors:  Andrew Schrepf; Stephanie Moser; Steven E Harte; Neil Basu; Chelsea Kaplan; Ellen Kolarik; Alexander Tsodikov; Chad M Brummett; Daniel J Clauw
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

Review 4.  The dynamic interaction between pain and opioid misuse.

Authors:  Adrianne R Wilson-Poe; Jose A Morón
Journal:  Br J Pharmacol       Date:  2017-06-28       Impact factor: 8.739

Review 5.  Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

Authors:  Mary-Ann Fitzcharles; Frank Petzke; Thomas R Tölle; Winfried Häuser
Journal:  Drugs       Date:  2021-11-20       Impact factor: 9.546

6.  Sensory sensitivity and symptom severity represent unique dimensions of chronic pain: a MAPP Research Network study.

Authors:  Andrew Schrepf; David A Williams; Robert Gallop; Bruce D Naliboff; Neil Basu; Chelsea Kaplan; Daniel E Harper; J Richard Landis; J Quentin Clemens; Eric Strachan; James W Griffith; Niloofar Afari; Afton Hassett; Michel A Pontari; Daniel J Clauw; Steven E Harte
Journal:  Pain       Date:  2018-10       Impact factor: 6.961

7.  Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation.

Authors:  Daniel S Albrecht; Anton Forsberg; Angelica Sandström; Courtney Bergan; Diana Kadetoff; Ekaterina Protsenko; Jon Lampa; Yvonne C Lee; Caroline Olgart Höglund; Ciprian Catana; Simon Cervenka; Oluwaseun Akeju; Mats Lekander; George Cohen; Christer Halldin; Norman Taylor; Minhae Kim; Jacob M Hooker; Robert R Edwards; Vitaly Napadow; Eva Kosek; Marco L Loggia
Journal:  Brain Behav Immun       Date:  2018-09-14       Impact factor: 7.217

8.  Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Sloan; Paul A Nuzzo; Laura C Fanucchi; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2019-06-15       Impact factor: 4.530

9.  Evoked Pressure Pain Sensitivity Is Associated with Differential Analgesic Response to Verum and Sham Acupuncture in Fibromyalgia.

Authors:  Noah A Zucker; Alex Tsodikov; Scott D Mist; Stephen Cina; Vitaly Napadow; Richard E Harris
Journal:  Pain Med       Date:  2017-08-01       Impact factor: 3.750

10.  Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation.

Authors:  Laurent F Martin; Aubin Moutal; Kevin Cheng; Stephanie M Washington; Hugo Calligaro; Vasudha Goel; Tracy Kranz; Tally M Largent-Milnes; Rajesh Khanna; Amol Patwardhan; Mohab M Ibrahim
Journal:  J Pain       Date:  2021-06-19       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.